• Led in vivo and ex vivo assay development for target validation and PK/PD assessment in CMT2A and ALS mouse models.• Designed and executed phenotypic screens for cell-based assays(primary cultured neurons and mouse embryonic fibroblasts).• Supervised and trained junior team members to perform image-based assays as well as mouse behavioral evaluation.• Pioneered the lab infrastructure as the first bench scientist, establishing vendor relationships, sourcing equipment, and developing lab operation protocols, fueling the company's early growth.• Authored IACUC animal protocols to meet all regulatory requirements and promote ethical animal research.

• Supervised and trained three junior scientists, fostering their skill development and contributing to a collaborative research environment. • Conducted phenotypic screening using a novel patient-derived iPSC co-culture assay to assess lead compounds' efficacy in promoting ALS phenotype survival and rescue.• Spearheaded the development and deployment of a single deep learning-based pipeline that quantified images across multiple imaging platforms. (Operetta, Incucyte, Cytation5, Cx7).• Established a new in vivo translational team, securing equipment, training personnel, and developing operational protocols to evaluate lead compounds in a 3k synucleinopathy Parkinson's mouse model.

• Performed high content RNAi screening of autism/schizophrenia rare-variant genes using 13-channel multiplexed imaging, identifying convergent changes in the molecular network of synapses.• Applied 13-channel multiplexed imaging to rat hippocampal neurons, revealing diverse synapse classes and distinct synapsin 1 regulation in excitatory/inhibitory synapses.• Collaborated effectively in a cross-functional team to integrate automated workflows for highthroughput imaging and data analysis, accelerating research progress.

• Designed innovative phenotypic screens to identify therapeutic pathways for ALS in primary cultured rodent cortical neuronal cultures.• Generated and characterized a new ALS mouse model that develops neurodegeneration prior to protein aggregation accumulation, offering new insights for mechanistic and therapeutic studies.• Discovered disruption of the actin cytoskeleton with ALS mutant proteins is linked to nuclear transport dysfunction, proposing actin targeting as a new therapeutic strategy for ALS.

• Employed a combination of electrophysiology and confocal microscopy to evaluate the functional consequences of mutations in scaffolding proteins on synaptic signaling in primary neurons and organotypic slices.• Characterized the function of S-SCAM at synapses, revealing its impact on synaptic transmission and revealing a potential mechanism for its role in early-onset schizophrenia. • Developed SynPAnal, an open-source software tool for the rapid quantification of synaptic puncta from fluorescence microscopy images, facilitating efficient data analysis.

• Maintained knockout mouse colony: performed animal husbandry, genotyping, oral dosing, plasma collection, tissue harvesting, tissue processing and analysis.• Characterized extra-renal production of vitamin D using a beta-galactose reporter gene in CYP27B1 null mice.• Examined the role calbindin D9k in vitamin D regulated intestinal calcium absorption.